Creative Planning
NAMS icon

Creative Planning’s NewAmsterdam Pharma NAMS Stock Holding History

Creative Planning’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276K Sell
8,135
-222
-3% -$7.32K ﹤0.01% 3637
2026
Q1 		$268K Sell
8,357
-7,280
-47% -$237K ﹤0.01% 3507
2025
Q4 		$549K Buy
+15,637
New +$569K ﹤0.01% 2760

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Creative Planning's NAMS Position: Q2 2026 in Review

Creative Planning reduced its NewAmsterdam Pharma (NAMS) stake by 2.7% in Q2 2026, selling an estimated $7.32K and leaving 8,135 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #3637.

Creative Planning first reported a position in NAMS in Q4 2025 and has held it in 3 quarters since. The position peaked at $549K in Q4 2025. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Creative Planning held 8,135 shares of NewAmsterdam Pharma worth $276K as of Q2 2026.
  • Creative Planning sold 222 NewAmsterdam Pharma shares in Q2 2026, an estimated $7.32K.
  • NewAmsterdam Pharma made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3637 holding.
  • Creative Planning first reported a position in NewAmsterdam Pharma in Q4 2025 and has held it in 3 quarters since.
  • Creative Planning's NewAmsterdam Pharma position peaked at $549K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.